BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9377851)

  • 1. [Authors' experience with transvaginal administration of progestagens].
    Cataldi U; Tridente V; Pazienza S; Brizzi C; Serrao L; Proia L; Quattrini MJ
    Clin Ter; 1997 Apr; 148(4):165-72. PubMed ID: 9377851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravaginal oestrogen and progestin administration: advantages and disadvantages.
    Cicinelli E
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):391-405. PubMed ID: 17981510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micronized progesterone and its impact on the endometrium and breast vs. progestogens.
    Gompel A
    Climacteric; 2012 Apr; 15 Suppl 1():18-25. PubMed ID: 22432812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routes of delivery for progesterone and progestins.
    Sitruk-Ware R
    Maturitas; 2007 May; 57(1):77-80. PubMed ID: 17368973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study.
    Ferrero S; Gerbaldo D; Fulcheri E; Cristoforoni P
    Minerva Ginecol; 2002 Dec; 54(6):519-30. PubMed ID: 12432337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uses of progesterone in clinical practice.
    Warren MP; Shantha S
    Int J Fertil Womens Med; 1999; 44(2):96-103. PubMed ID: 10338267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of micronized progesterone on the endometrium: a systematic review.
    Stute P; Neulen J; Wildt L
    Climacteric; 2016 Aug; 19(4):316-28. PubMed ID: 27277331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of combined oral hormone replacement therapy in postmenopausal symptoms].
    Szántó F; Hörömpöli C
    Orv Hetil; 1996 May; 137(20):1079-81. PubMed ID: 8657419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.
    Sitruk-Ware R
    Climacteric; 2007 Oct; 10(5):358-70. PubMed ID: 17852138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial response to a cyclic regimen of percutaneous 17beta-estradiol and low-dose vaginal micronized progesterone in women with mild-to-moderate hypertension.
    Vilodre LC; Osório Wender MC; Sisson de Castro JA; dos Reis FM; Ruschel S; Magalhães JA; Spritzer PM
    Gynecol Endocrinol; 2003 Aug; 17(4):323-8. PubMed ID: 14503977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral administration of progestins for hormonal replacement therapy.
    Nath A; Sitruk-Ware R
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):88-96. PubMed ID: 19340703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women.
    Bernardi F; Pieri M; Stomati M; Luisi S; Palumbo M; Pluchino N; Ceccarelli C; Genazzani AR
    Gynecol Endocrinol; 2003 Feb; 17(1):65-77. PubMed ID: 12724021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.